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Introduction {#sec001}
============

Patients with cirrhosis are considered immunocompromised and susceptible to various bacterial infections that may aggravate the major complications of cirrhosis \[[@pone.0229101.ref001]\]. Therefore, preventing infections is considered a constitutive part of patient care, and all the relevant practice guidelines and consensus statements recommend antibiotic prophylaxis for all patients with cirrhosis in specific settings, including secondary prophylaxis for patients with previous spontaneous bacterial peritonitis (SBP) and primary prophylaxis for patients with poor liver function and those with active upper gastrointestinal (UGI) bleeding \[[@pone.0229101.ref002]--[@pone.0229101.ref004]\]. The role of prophylactic antibiotics is critical in patients with cirrhosis and UGI bleeding because bacterial infections during or immediately after bleeding episodes are associated with severe complications, such as failure to control bleeding, rebleeding, and mortality during hospitalization \[[@pone.0229101.ref005]--[@pone.0229101.ref007]\].

Prophylactic antibiotics have substantial benefits in patients with cirrhosis and UGI bleeding; consequently, prophylactic antibiotics have been endorsed by major clinical practice guidelines \[[@pone.0229101.ref002]--[@pone.0229101.ref004]\]. However, excessive antibiotic use is associated with side effects, including drug toxicity, drug--drug interaction, and *Clostridium difficile* infection \[[@pone.0229101.ref008]\]. Moreover, a recent study demonstrated that antibiotic prophylaxis in hospitalized patients with cirrhosis may increase the risk of subsequent infection \[[@pone.0229101.ref009]\]. Therefore, a balance of the risks and benefits of routine and indistinctive prophylactic antibiotic use in all patients with cirrhosis and UGI bleeding is essential. In the 2000s, numerous patients with cirrhosis-related ascites did not receive recommended services, including prophylactic antibiotics, during UGI bleeding \[[@pone.0229101.ref010]\]. Taking advantage of this situation, the authors of the present study have observed that not all patients had identical bacterial infection risk without prophylactic antibiotic use.

In patients with cirrhosis and portal hypertension, risk stratification and personalized care have become primary strategies in the current stratified medicine era \[[@pone.0229101.ref004],[@pone.0229101.ref011]\]. In recent years, patients with cirrhosis of varying severity may have disparate levels of risk of complications during UGI bleeding; therefore, such patients have varying needs for prophylactic antibiotics \[[@pone.0229101.ref012],[@pone.0229101.ref013]\]. The risk of cirrhosis-related complications, including gastroesophageal variceal hemorrhage, mainly depends on the degree of portal hypertension, which is proportional to the severity of cirrhosis \[[@pone.0229101.ref014]\]. The Child--Pugh score is the simplest and most effective tool for assessment of bedside prognosis in patients with cirrhosis \[[@pone.0229101.ref012],[@pone.0229101.ref015]\]. In this study, we reappraised whether a stratified, rather than indiscriminate, prophylactic antibiotic use strategy, based on the Child--Pugh score, is applicable in patients with cirrhosis and UGI bleeding.

Materials and methods {#sec002}
=====================

Study patients and data collection {#sec003}
----------------------------------

In this retrospective study, we analyzed all patients with cirrhosis aged ≥ 20 years who underwent upper endoscopy for UGI bleeding between January 2003 and December 2014 at Chang Gung Memorial Hospital, a tertiary referral hospital in Chiayi, southern Taiwan. Data were retrieved from the hospital's computer archives; the electronic medical records of all eligible patients were reviewed to obtain necessary data, including clinical data, demographic characteristics, and laboratory examination results. The study endpoints included 14-day infection and rebleeding rates and 42-day mortality rate. All patient records were traced until day 42 (end of week 6) or death. The exclusion criteria were (1) bacterial infection on the day of UGI bleeding, (2) antibiotic use within 1 week before UGI bleeding, (3) Child--Pugh class C (score ≥ 10), and (4) death within the first 24 h. To prevent the recording of redundant demographic variables, only the first UGI bleeding episode in patients with multiple UGI bleeding episodes was included for analysis as the index bleeding episode. Because the present study was retrospective without specific interventions for the study patients, the requirement for informed consent was waived. All patient data were fully anonymized before access and this study was approved by the Chang Gung Medical Foundation Institutional Review Board (IRB No: 201701786B0).

Management program {#sec004}
------------------

Since the inauguration of Chang Gung Memorial Hospital, Chiayi branch (i.e., the study site) in 2002, upper endoscopy using a video endoscope (GIF-Q240Z, Olympus, Tokyo, Japan) and an electronic endoscopic system, either the EVIS 240 series (Olympus) or the EVIS 260 series (Olympus) with endoscopic hemostasis within 24 h (usually within 12 h) has been the standard of care for all patients with UGI bleeding due to any etiology. Endoscopic hemostasis is achieved using measures, including band ligation, injection sclerosis, and coagulation, depending on the clinical scenario and operators' decisions. The vasoactive drug terlipressin (Glypressin, Ferring AB, Malmö, Sweden) with or without intravenous proton pump inhibitor (PPI) use is generally initiated before endoscopy if the medical history and clinical picture suggests portal hypertension. After endoscopy, patients receive terlipressin at 1 mg/6 h for 3 days for UGI bleeding due to portal hypertension and intravenous PPI (omeprazole or pantoprazole 80 mg bolus loading and 40 mg twice daily for 1--3 days) due to peptic ulcers. Oral PPI is given for 2--4 months for patients with peptic ulcer disease. Patients may undergo repeat endoscopy or surgical devascularization if the initial endoscopic therapy fails. Secondary prophylaxis with the oral β-blocker propranolol is initiated as soon as variceal bleeding stops, provided no contraindication is noted. Decisions regarding the use and choice of prescribed antibiotics are taken by the clinicians in charge, most of whom are from the emergency department.

Definition {#sec005}
----------

We defined antibiotic prophylaxis as antibiotic prescription following bleeding in the absence of clinical signs of bacterial infection. Liver cirrhosis was diagnosed on the basis of the presence of esophageal or gastric varices observed through endoscopy with compatible image characteristics and clinical features indicating portal hypertension, such as splenomegaly, hepatic dysfunction, or thrombocytopenia. The patients were classified according to liver disease etiologies, namely hepatitis B virus (HBV) hepatitis (presence of the HBV surface antigen in the serum), hepatitis C virus (HCV) hepatitis (presence of the HCV antibody in the serum), dual HBV and HCV hepatitis (BC) hepatitis (presence of both HBV and HCV), and non-BC hepatitis (NBNC; negative for both HBV and HCV). The cause of UGI bleeding, either portal hypertension (gastric or esophageal varices) or peptic ulcers, was determined after endoscopy revealed active bleeding or stigmata of recent hemorrhage accompanied by a reduction in hemoglobin levels. Rebleeding was diagnosed when bleeding recurred more than 24 h after the initial bleeding episode had been controlled. The diagnoses of bacterial infections were made based on the standard guidelines \[[@pone.0229101.ref016]\], In addition, SBP was defined as an ascites polymorphonuclear cell count of ≥250 cells/mm^3^ and/or positive ascitic fluid culture. Common skin flora, particularly coagulase-positive staphylococci, was considered contaminants unless blood cultures were positive on two or more occasions or clinical signs of the relevant infection were observed.

Statistical analysis {#sec006}
--------------------

Continuous variables are expressed as means ± standard deviations. The qualitative and quantitative differences between the groups were analyzed using the chi-square or Fisher exact test for categorical parameters and the Student *t* test for continuous parameters. The multivariate logistic regression model was used to identify independent risk factors. Receiver operating characteristic (ROC) curves were employed to assess the performance characteristics of the Child--Pugh and model for end-stage liver disease (MELD) scores in predicting the acquisition of infection. All statistical tests were performed using SPSS (version 22.0; IBM, Chicago, IL, USA). A two-tailed *P* \< 0.05 was considered significant. Because antibiotics are theoretically more likely to be prescribed to patients with more severe cirrhosis, propensity scores (PPS) were calculated using antibiotic prophylaxis as the outcome variable in a multivariate logistic regression model.

Results {#sec007}
=======

Patient characteristics {#sec008}
-----------------------

[Fig 1](#pone.0229101.g001){ref-type="fig"} presents the flow of all included patients. In total, 1741 patients presented to the study site and had 4059 UGI bleeding episodes between January 2003 and December 2014. After the exclusion of 102 patients with active bacterial infections, 130 with recent antibiotic use, 37 who died within 24 h, and 559 with Child--Pugh class C scores, the remaining 913 were enrolled for analysis. Of these 913 patients, 73 received antibiotic prophylaxis and 840 did not. Of the 73 patients who received antibiotic prophylaxis, 19 received cefazolin, 4 received cefazolin plus gentamicin, 6 received cefuroxime, and 44 received ceftriaxone. The baseline characteristics of these 913 patients with Child--Pugh A/B scores are listed in [Table 1](#pone.0229101.t001){ref-type="table"}. Their mean age was 59.49 ± 13.15 years, and the male-to-female ratio was 2.42:1. Those who received antibiotic prophylaxis were younger (55.22 ± 12.46 vs. 59.86 ± 13.15 years, *P* = 0.003), had more units of blood transfusion (3.38 ± 2.78 vs. 2.43 ± 2.44 units, *P* = 0.006), had higher white blood cell counts (9.87 ± 4.28 vs. 7.92 ± 4.18 ×10^3^/μL, *P* \< 0.001), had lower systolic blood pressure (112.47 ± 27.24 vs. 121.37 ± 31.03 mmHg, *P* = 0.007), had a higher rate of intensive care unit admission (9.6% vs. 2.3%, *P* \< 0.001), and had a higher rate of portal hypertension-related (variceal) bleeding (93.10% vs. 77.14%, *P* = 0.001). The patients who received and did not receive antibiotic prophylaxis did not differ significantly in terms of sex, presence of hepatocellular carcinomas (HCCs), Child--Pugh scores, MELD scores, prior SBP, duration of hospitalization, and rates of 14-day infection, 14-day rebleeding, and 42-day mortality. Because this study was conducted over a long 12-year period, we divided the patients into two groups according to the period of UGI bleeding to understand whether there were differences in patient characteristics over time. As shown in [Table 2](#pone.0229101.t002){ref-type="table"}, compared with patients who presented between 2003 and 2008, patients who presented between 2009 and 2014 were older (58.43 ± 12.98 vs. 60.70 ± 13.26 years, *P* = 0.009), had a higher rate of prophylactic antibiotic use (2.9% vs. 13.8%, *P* \< 0.001), had shorter duration of hospitalization (6.92 ± 5.24 vs. 6.21 ± 5.71 days, *P* = 0.05), and had a lower Child--Pugh score (7.40 ± 1.18 vs. 7.22 ± 1.22, *P* = 0.0027). A similar insignificant difference in rates of 14-day infection, 14-day rebleeding, and 42-day mortality was observed separately in both Child--Pugh class A and class B patients ([S1 Table](#pone.0229101.s001){ref-type="supplementary-material"}). We also analyzed the 716 patients with portal hypertensive bleeding as a separate group, and the baseline characteristics of these patients are listed in [S2 Table](#pone.0229101.s002){ref-type="supplementary-material"}.

![Flow of patient enrollment.](pone.0229101.g001){#pone.0229101.g001}

10.1371/journal.pone.0229101.t001

###### Baseline patient characteristics.

![](pone.0229101.t001){#pone.0229101.t001g}

  Patient characteristics              Prophylaxis           No prophylaxis   All patients     *P* [^†^](#t001fn001){ref-type="table-fn"}   
  ------------------------------------ --------------------- ---------------- ---------------- -------------------------------------------- --
  Age, mean ± SD (years)               55.22 ± 12.46         59.86 ± 13.15    59.49 ± 13.15    0.003                                        
  Sex, male *n* (%)                    57 (78.1)             592 (70.5)       649 (71.1)       0.169                                        
  HCC, *n* (%)                         19 (26.0)             287 (34.2)       306 (33.5)       0.158                                        
  Blood transfused in 48 h, unit       3.38 ± 2.78           2.43 ± 2.44      2.51 ± 2.48      0.006                                        
  Ascites, *n* (%)                     33 (45.2)             344 (41.0)       377 (41.3)       0.479                                        
  Hepatic encephalopathy, *n* (%)      6 (8.2)               41 (4.9)         47 (5.1)         0.216                                        
  Prior SBP, *n* (%)                   1 (1.4)               17 (2.0)         18 (2.0)         0.700                                        
  Etiology of cirrhosis, *n* (%)                                                               0.211                                        
                                       HBV                   22 (30.1)        173 (20.5)       195 (21.3)                                   
                                       HCV                   28 (38.4)        404 (48.2)       432 (47.2)                                   
                                       BC                    8 (11.0)         77 (9.2)         85 (9.2)                                     
                                       NBNC                  15 (20.5)        186 (22.1)       201 (22.3)                                   
  Platelet count, ×10^3^/μL            114.51 ± 68.49        112.25 ± 70.31   112.43 ± 70.13   0.788                                        
  White blood cell count, ×10^3^/μL    9.87 ± 4.28           7.92 ± 4.18      8.06 ± 4.22      \<0.001                                      
  Hemoglobin, g/L                      9.37 ± 2.26           9.21 ± 2.52      9.22 ± 2.50      0.593                                        
  International normalized ratio       1.32 ± 0.17           1.27 ± 0.45      1.28 ± 0.44      0.351                                        
  Sodium, mEq/L                        137.00 ± 4.00         136.56 ± 10.81   136.59 ± 10.42   0.724                                        
  Creatinine, mg/L                     1.15 ± 0.76           1.28 ± 1.25      1.27 ± 1.22      0.379                                        
  Bilirubin, mg/dL                     1.81 ± 1.04           1.78 ± 1.15      1.78 ± 1.14      0.829                                        
  ALT, IU/L                            47.15 ± 24.89         65 ± 125.50      62.93 ± 120.40   0.229                                        
  Albumin, g/dL                        2.97 ± 0.47           2.91 ± 0.55      2.91 ± 0.54      0.301                                        
  Systolic blood pressure, mmHg        112.47 ± 27.24        121.37 ± 31.03   120.62 ± 30.81   0.019                                        
  Heart rate, beats/min                105.01 ± 21.48        100.31 ± 21.60   94.68 ± 31.40    0.079                                        
  Etiology of bleeding, *n* (%)                                                                0.001                                        
                                       Portal hypertension   68 (93.1)        648 (77.14)      716 (78.4)                                   
                                       Peptic ulcer          5 (6.9)          192 (22.86)      197 (21.6)                                   
  Hospitalization days                 7.33 ± 6.79           6.50 ± 5.40      6.56 ± 5.53      0.218                                        
  ICU admission, *n* (%)               7 (9.6)               19 (2.3)         26 (2.84)        \<0.001                                      
  MELD score                           12.85 ± 3.84          12.53 ± 3.71     12.59 ± 3.79     0.480                                        
  Child--Pugh score                    7.34 ± 1.20           7.32 ± 1.21      7.32 ± 1.21      0.855                                        
  Child--Pugh class A/B, *n* (%)       18/55                 239/601          257/656          0.489                                        
  (24.7/75.3)                          (28.5/71.5)           (28.1/71.9)                                                                    
  Infection within 14 days, *n* (%)    5 (6.8)               40 (4.8)         45 (4.9)         0.429                                        
  Rebleeding within 14 days, *n* (%)   5 (6.8)               71 (8.5)         76 (8.3)         0.634                                        
  Mortality within 42 days, *n* (%)    5 (6.8)               27 (3.2)         32 (3.5)         0.161                                        

^†^ Comparison between antibiotic prophylaxis and no prophylaxis groups

*Abbreviations*: *SD*, standard deviation; *HCC*, hepatocellular carcinoma; *SBP*, spontaneous bacterial peritonitis; *HBV*, hepatitis B virus; *HCV*, hepatitis C virus; *BC*, presence of both HBV and HCV; *NBNC*, negative for both HBV and HCV; *ALT*, alanine aminotransferase; *ICU*, intensive care unit; *MELD*, model for end-stage liver disease.

10.1371/journal.pone.0229101.t002

###### Changes in patient characteristics and results over time.
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                                       2003--2008 (n = 487)   2009--2014 (n = 426)   *P* [^†^](#t002fn001){ref-type="table-fn"}
  ------------------------------------ ---------------------- ---------------------- --------------------------------------------
  Age, mean ± SD (years)               58.43 ± 12.98          60.70 ± 13.26          0.009
  Sex, male *n* (%)                    351 (72.1)             298 (70)               0.527
  Prophylaxis, *n* (%)                 14 (2.9)               59 (13.8)              \<0.001
  Hepatocellular carcinoma, *n* (%)    159 (32.6)             147 (34.5)             0.601
  Blood transfused in 48 h, unit       2.45 ± 2.47            2.57 ± 2.48            0.475
  Ascites, *n* (%)                     203 (41.7)             174 (40.8)             0.850
  Hepatic encephalopathy, *n* (%)      27 (5.5)               20 (4.7)               0.668
  Platelet count, ×10^3^/μL            110.58 ± 76.93         114.55 ± 61.44         0.393
  Hemoglobin, g/L                      9.32 ± 2.31            9.10 ± 2.69            0.187
  Creatinine, mg/L                     1.28 ± 1.22            1.21 ± 1.21            0.762
  Hospitalization days                 6.92 ± 5.24            6.21 ± 5.71            0.05
  MELD score                           12.69 ± 3.76           12.40 ± 3.66           0.246
  Child--Pugh score                    7.40 ± 1.18            7.22 ± 1.22            0.027
  Infection within 14 days, *n* (%)    33 (6.8)               12 (2.8)               0.09
  Rebleeding within 14 days, *n* (%)   39 (8)                 37 (8.7)               0.803
  Mortality within 42 days, *n* (%)    18 (3.7)               14 (3.3)               0.722
  Body mass index (kg/m^2^)            24.87 ± 3.71           24.85 ± 3.88           0.918
  Diabetes mellitus, *n* (%)           163 (33.5)             169 (39.7)             0.061
  ICU admission, *n* (%)               11 (2.3)               15 (3.5)               0.345

^†^ Comparison between patients enrolled during 2003--2008 and 2009--2014.

*Abbreviations*: *SD*, standard deviation; *ICU*, intensive care unit; *MELD*, model for end-stage liver disease.

Factors associated with risk of 14-day infection {#sec009}
------------------------------------------------

During the 11-year observation period, only 45 (4.9%) of the enrolled 913 patients exhibited confirmed bacterial infection within 14 days of presentation at the hospital ([Table 3](#pone.0229101.t003){ref-type="table"}). [Table 4](#pone.0229101.t004){ref-type="table"} lists bacterial infection types in these 45 patients. No significant reduction was observed in the risk of acquiring bacterial infection in the patients who received antibiotic prophylaxis compared with those who did not (relative risk \[RR\]: 0.932, 95% confidence interval \[CI\]: 0.300--2.891, *P* = 0.902). There was also no significant difference in infection risk with respect to prophylactic antibiotic use when Child--Pugh class A and class B patients were analyzed separately ([S3 Table](#pone.0229101.s003){ref-type="supplementary-material"}). Except for white blood cell counts (RR: 1.102, 95% CI: 1.016--1.194, *P* = 0.019), platelet counts (RR: 0.991, 95% CI: 0.983--0.998, *P* = 0.019), albumin levels (RR: 0.434, 95% CI: 0.195--0.965, *P* = 0.041), and MELD scores (RR: 1.132, 95% CI: 1.033--1.241, *P* = 0.008), all clinical and laboratory parameters---including age, sex, ascites, previous SBP, blood pressure, hemoglobin levels, presence of HCC, intensive care unit admission, Child--Pugh score, etiology of cirrhosis, cause of UGI bleeding, and endoscopic therapy---did not affect the RR of bacterial infection ([Table 3](#pone.0229101.t003){ref-type="table"}). After PPS adjustment with antibiotic prophylaxis as the outcome variable, 138 patients who received and did not receive antibiotic prophylaxis were obtained at a ratio of 1:1, forming two groups with 69 patients each. Among the 138 patients, 9 had bacterial infection; risk of infection did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.962, 95% CI: 0.147--6.288, *P* = 0.968). [Fig 2](#pone.0229101.g002){ref-type="fig"} presents the ROC curves and areas under the ROC curves (AUCs) of the Child--Pugh and MELD scores for predicting bacterial infection. Among the patients with cirrhosis with Child--Pugh scores of 5--9 and UGI bleeding, neither the Child--Pugh score nor the MELD score was an optimal tool for predicting bacterial infection because the AUCs (95% CIs) of the Child--Pugh and MELD scores were 0.610 (0.529--0.691) and 0.666 (0.591--0.742), respectively---both \<0.7. When only the 716 portal hypertensive bleeding patients were included, the risk of 14-day infection did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.827, 95% CI: 0.233--2.937, *P* = 0.769) as shown in [S4 Table](#pone.0229101.s004){ref-type="supplementary-material"}.

![ROC curves for Child--Pugh scores of 5--9 and the corresponding MELD scores for predicting bacterial infection.\
The AUCs were 0.610 (95% CI: 0.529--0.691, *P* = 0.013) and 0.666 (95% CI: 0.591--0.742, *P* \< 0.001) for the Child--Pugh and MELD scores, respectively. Abbreviations: ROC, receiver operating characteristic; AUC, area under the ROC curve; MELD, model for end-stage liver disease; CI, confidence interval.](pone.0229101.g002){#pone.0229101.g002}

10.1371/journal.pone.0229101.t003

###### Factors associated with bacterial infection risk within 14 days[^†^](#t003fn001){ref-type="table-fn"}.
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  Factors                     All patients (n = 913)   PPS-matched patients (n = 138)                                                             
  --------------------------- ------------------------ -------------------------------- -------------- -------- ---------------- ---------------- -------
  Prophylaxis, y/n            0.932                    0.300--2.891                     0.902          0.962    0.147--6.288     0.968            
  Age, years                  1.015                    0.985--1.047                     0.325          1.011    0.907--1.128     0.840            
  Sex, male/female            0.671                    0.317--1.418                     0.296          2.233    0.184--27.056    0.528            
  Prior SBP, y/n              1.213                    0.138--10.682                    0.862          --       --               0.999            
  Ascites, y/n                1.300                    0.563--3.003                     0.539          0.964    0.048--19.292    0.981            
  HCCs, y/n                   1.197                    0.592--2.419                     0.616          0.394    0.032--4.869     0.468            
  Blood transfusion, unit     1.011                    0.874--1.169                     0.885          0.919    0.619--1.364     0.676            
  Encephalopathy, y/n         1.084                    0.282--4.169                     0.906          0.070    0.001--6.825     0.255            
  Blood pressure, mmHg        1.001                    0.989--1.012                     0.930          1.024    0.985--1.064     0.224            
  Hemoglobin, g/L             1.119                    0.933--1.342                     0.227          1.156    0.611--2.187     0.655            
  WBC count, ×10^3^/μL        1.102                    1.016--1.194                     0.019          1.260    0.832--1.910     0.275            
  Platelet count, ×10^3^/μL   0.991                    0.983--0.998                     0.019          0.955    0.908--1.005     0.078            
  Albumin, g/dL               0.434                    0.195--0.965                     0.041          0.920    0.055--15.374    0.954            
  ICU admission, y/n          0.298                    0.077--1.145                     0.078          17.131   0.557--526.696   0.104            
  MELD score                  1.132                    1.033--1.241                     0.008          0.979    0.665--1.441     0.913            
  Child Pugh score            0.890                    0.563--1.409                     0.619          3.514    0.489--25.242    0.212            
  Etiology of cirrhosis                                                                 0.670                                    0.767            
                              NBNC                     1.000                                                    1.000                             
                              HBV                      2.046                            0.641--6.532   0.227    1.220            0.062--24.122    0.896
                              HCV                      1.693                            0.573--5.001   0.341    3.477            0.242--49.912    0.359
                              BC                       1.395                            0.301--6.463   0.670    --               --               0.998
  Treatment                                                                             0.544                                    0.988            
                              No treatment             1.000                                                    1.000                             
                              APC                      1.892                            0.496--7.209   0.350    1.150            0.008--170.674   0.956
                              EVL                      0.929                            0.385--2.242   0.870    0.728            0.064--8.229     0.798
                              EIS                      1.395                            0.301--6.463   0.670    1.058            0.082--13.609    0.965
  Etiology of bleeding                                                                  0.250                                    0.999            
                              Portal hypertension      1.000                                                    1.000                             
                              Peptic ulcer             0.468                            0.128--1.705   0.250    --               --               

^†^ Number of patients with 14-day infection: 45 of all 913 patients and 9 of the 138 PPS-matched patients.

*Abbreviations*: *PPS*, propensity score; *RR*, relative risk; *CI*, confidence interval; *y/n*, yes/no; *SBP*, spontaneous bacterial peritonitis; *HCC*, hepatocellular carcinoma; *WBC*, white blood cell; *ICU*, intensive care unit; *MELD*, model for end-stage liver disease; *NBNC*, negative for both HBV and HCV; *HBV*, hepatitis B virus; *HCV*, hepatitis C virus; *BC*, presence of both HBV and HCV; *APC*, argon plasma coagulation; *EVL*, endoscopic variceal ligation; *EIS*, endoscopic injection sclerosis.

10.1371/journal.pone.0229101.t004

###### Types of bacterial infection within 14 days (n = 45).
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  Type                        No   Site and bacteria                   
  --------------------------- ---- ----------------------------------- ----------------------------------
  SBP                         7    Blood                               Ascites
                              1    *Bacteroides thetaiotaomicron*      *Bacteroides thetaiotaomicron*
                              2    *Escherichia coli*                  --
                              1    Group B streptococci                --
                              1    --                                  Viridans streptococci
                              2    --                                  --
  Pneumonia                   7    Blood                               Sputum
                              2    --                                  *Haemophilus influenza*
                              1    --                                  *Acinetobacter baumannii*
  ORSA                                                                 
                              1    *Staphylococcus aureus*             --
                              1    *Staphylococcus aureus*             --
  Viridans streptococci                                                
                              2    --                                  --
  UTI                         12   Blood                               Urine
                              1    *Acinetobacter baumannii*           --
  *Escherichia coli*                                                   
                              1    --                                  Gram-positive cocci (2 types)
                              1    *Klebsiella pneumoniae*             *Klebsiella pneumoniae*
                              1    *Acinetobacter baumannii*           *Serratia marcescens*
                              1    --                                  Coagulase-negative staphylococci
                              1    --                                  *Klebsiella pneumoniae*
                              1    *Escherichia coli*                  --
                              1    *Bacillus* spp.                     *Enterococcus faecalis*
                              1    *Escherichia coli*                  *Escherichia coli*
                              3    --                                  --
  Cellulitis                  2    Blood                               
                              1    *Staphylococcus aureus*             --
                              1    *Klebsiella pneumoniae*             --
  Arthritis                   2    Blood                               Synovial fluid
                              1    --                                  *Staphylococcus aureus*
                              1    Group B streptococci                --
  Unknown                     15   Blood                               
                              1    *Stenotrophomonas maltophilia*      --
                              2    *Klebsiella pneumoniae*             --
                              1    *Salmonella enterica* Serogroup B   --
  Viridans streptococci                                                
  *Peptostreptococcus* spp.                                            
                              3    *Staphylococcus aureus*             --
                              1    *Aeromonas caviae*                  --
                              1    *Vibrio vulnificus*                 --
                              2    *Escherichia coli*                  --
                              2    Viridans streptococci               --
                              1    *Streptococcus pneumoniae*          --
                              1    *Enterobacter cloacae*              --

*Abbreviations*: *SBP*, spontaneous bacterial peritonitis; *UTI*, urinary tract infection; *ORSA*, oxacillin-resistant *Staphylococcus aureus*.

Factors associated with risk of 14-day rebleeding {#sec010}
-------------------------------------------------

In this study, 76 of the 913 original patients and 12 of the 138 PPS-matched patients experienced rebleeding within 14 days of presentation at the hospital. [Table 5](#pone.0229101.t005){ref-type="table"} summarizes the RRs of all factors associated with this rebleeding. Among the 913 patients, the factors significantly affecting the RRs of rebleeding were units of blood transfusion (RR: 1.185, 95% CI: 1.055--1.332, *P* = 0.004), albumin levels (RR: 0.500, 95% CI: 0.255--0.981, *P* = 0.004), and treatment with endoscopic variceal ligation (RR: 0.455, 95% CI: 0.240--0.865, *P* = 0.016). Antibiotic prophylaxis did not affect the RR of rebleeding (RR: 0.791, 95% CI: 0.287--2.181, *P* = 0.650) ([Table 5](#pone.0229101.t005){ref-type="table"} and [S3 Table](#pone.0229101.s003){ref-type="supplementary-material"}). The risk of 14-day rebleeding did not differ significantly between the patients who received and did not receive antibiotic prophylaxis after PPS adjustment (RR: 0.292, 95% CI: 0.050--1.171, *P* = 0.173). When only the 716 portal hypertensive bleeding patients were included, the risk of 14-day rebleeding did not differ significantly between those who received and did not receive antibiotic prophylaxis (RR: 0.696, 95% CI: 0.223--2.170, *P* = 0.533) as shown in [S5 Table](#pone.0229101.s005){ref-type="supplementary-material"}.

10.1371/journal.pone.0229101.t005

###### Factors associated with risk of rebleeding within 14 days[^†^](#t005fn001){ref-type="table-fn"}.

![](pone.0229101.t005){#pone.0229101.t005g}

  Factors                     All patients (n = 913)   PPS-matched patients (n = 138)                                                             
  --------------------------- ------------------------ -------------------------------- -------------- -------- ---------------- ---------------- -------
  Prophylaxis                 0.791                    0.287--2.181                     0.650          0.292    0.050--1.171     0.173            
  Age, years                  0.992                    0.287--2.181                     0.483          0.990    0.905--1.083     0.825            
  Sex, male/female            1.891                    0.9807--3.648                    0.057          11.969   0.737--194.294   0.081            
  Prior SBP, y/n              --                       --                               0.998          --       --               0.999            
  Ascites, y/n                1.944                    0.950--3.980                     0.069          0.524    0.022--12.606    0.690            
  HCCs, y/n                   1.131                    0.640--1.998                     0.672          0.461    0.047--4.564     0.508            
  Blood transfusion, unit     1.185                    1.055--1.332                     0.004          1.242    0.861--1.792     0.247            
  Encephalopathy, y/n         0.690                    0.189--2.514                     0.573          1.166    0.057--23.708    0.920            
  Blood pressure, mmHg        0.996                    0.987--1.005                     0.379          1.104    0.968--1.403     0.320            
  Hemoglobin, g/L             1.039                    0.909--1.187                     0.578          1.057    0.649--1.721     0.824            
  WBC count, ×10^3^/μL        0.927                    0.853--1.008                     0.076          0.828    0.621--1.015     0.200            
  Platelet count, ×10^3^/μL   1.002                    0.999--1.006                     0.240          1.103    0.995--1.032     0.168            
  Albumin, g/dL               0.500                    0.255--0.981                     0.004          0.988    0.097--10.106    0.992            
  ICU admission, y/n          0.914                    0.236--3.530                     0.896          0.426    0.014--12.662    0.622            
  MELD score                  0.910                    0.910--0.831                     0.042          0.674    0.447--1.016     0.059            
  Child Pugh score            0.978                    0.657--1.455                     0.912          5.330    0.827--34.348    0.078            
  Etiology of cirrhosis                                                                 0.262                                    0.421            
                              NBNC                     1.000                                                    1.000                             
                              HBV                      1.019                            0.411--2.527   0.968    7.168            0.420--122.290   0.174
                              HCV                      1.830                            0.831--4.027   0.133    2.762            0.156--48.989    0.489
                              BC                       1.750                            0.641--4.777   0.275    0.754            0.014--40.663    0.885
  Treatment                                                                             0.098                                    0.669            
                              No treatment             1.000                                                    1.000                             
                              APC                      0.991                            0.334--2.944   0.988    --               --               0.999
                              EVL                      0.455                            0.240--0.865   0.016    3.403            0.165--70.014    0.427
                              EIS                      0.809                            0.367--1.782   0.599    6.578            0.311--139.036   0.226
  Etiology of bleeding                                                                  0.294                                    0.213            
                              Portal hypertension      1.000                                                    1.000                             
                              Peptic ulcer             0.585                            0.214--1.599            11.041           0.250--496.156   

^†^ Number of patients with 14-day rebleeding: 76 of all 913 patients and 12 of the 138 PPS-matched patients.

*Abbreviations*: *PPS*, propensity score; *RR*, relative risk; *CI*, confidence interval; *y/n*, yes/no; *SBP*, spontaneous bacterial peritonitis; *HCC*, hepatocellular carcinoma; *WBC*, white blood cell; *ICU*, intensive care unit; *MELD*, model for end-stage liver disease; *NBNC*, negative for both HBV and HCV; *HBV*, hepatitis B virus; *HCV*, hepatitis C virus; *BC*, presence of both HBV and HCV; *APC*, argon plasma coagulation; *EVL*, endoscopic variceal ligation; *EIS*, endoscopic injection sclerosis.

Factors associated with the risk of 42-day mortality {#sec011}
----------------------------------------------------

Among the 913 original patients and 138 PPS-matched patients, 32 and 6 exhibited 42-day mortality, respectively. In the 32 patients, the causes of mortality were potentially multifactorial, with major causes being infection, refractory bleeding, aortic dissection, acute myocardial infarction, and acute on chronic liver failure in 7, 4, 1, 1, and 19 patients, respectively. The 42-day mortality rate was approximately 3.5% in the patients with Child--Pugh A/B cirrhosis and UGI bleeding. As shown in [Table 6](#pone.0229101.t006){ref-type="table"}, except for the presence of HCCs (RR: 5.300, 95% CI: 1.850--15.187, *P* = 0.002) and platelet counts (RR: 1.006, 95% CI: 1.002--1.010, *P* = 0.003), no clinical and laboratory parameters, including antibiotic prophylaxis (RR: 2.710, 95% CI: 0.769--9.524, *P* = 0.121), affected the RR of 42-day mortality. Antibiotic prophylaxis similarly did not significantly affect risk of 42-day mortality in Child--Pugh Class B patient subgroup (RR: 2.681, 95% CI: 0.761--9.434, *P* = 0.125; [S3 Table](#pone.0229101.s003){ref-type="supplementary-material"}). Because the number of cases of 42-day mortality was low in the PPS-matched cohort, the RRs and their corresponding 95% CIs were incalculable for all factors. However, no factors, including antibiotic prophylaxis, significantly affected the RRs of 42-day mortality after adjustment for PPS (*P* = 0.994--1.000). The use of prophylactic antibiotics did not affect the 42-day mortality (RR: 2.304, 95% CI: 0.558--9.521, *P* = 0.249) when only the 716 portal hypertensive bleeding patients were included for analysis as demonstrated in [S6 Table](#pone.0229101.s006){ref-type="supplementary-material"}.

10.1371/journal.pone.0229101.t006

###### Factors associated with risk of mortality within 42 days[^†^](#t006fn001){ref-type="table-fn"}.

![](pone.0229101.t006){#pone.0229101.t006g}

  Factors                     All patients (n = 913)   PPS match (n = 138)                                           
  --------------------------- ------------------------ --------------------- --------------- ------- ------- ------- -------
  Prophylaxis, y/n            2.710                    0.769--9.524          0.121           --      --      0.998   
  Age, years                  0.991                    0.951--1.032          0.656           --      --      0.994   
  Sex, male/female            0.860                    0.295--2.508          0.782           --      --      0.998   
  Prior SBP, y/n              --                       --                    0.998           --      --      1.000   
  Ascites, y/n                0.994                    0.329--3.001          0.992           --      --      0.999   
  HCCs, y/n                   5.300                    1.850--15.187         0.002           --      --      0.997   
  Blood transfusion, unit     1.085                    0.901--1.305          0.389           --      --      0.999   
  Encephalopathy, y/n         2.218                    0.575--8.557          0.247           --      --      0.999   
  Blood pressure, mmHg        0.997                    0.982--1.013          0.736           --      --      0.997   
  Hemoglobin, g/L             1.043                    0.830--1.309          0.720           --      --      1.000   
  WBC count, ×10^3^/μL        0.915                    0.807--1.038          0.169           --      --      0.999   
  Platelet count, ×10^3^/μL   1.006                    1.002--1.010          0.003           --      --      1.000   
  Albumin, g/dL               0.407                    0.143--1.154          0.091           --      --      1.000   
  ICU admission, y/n          4.338                    0.997--18.867         0.050           --      --      1.000   
  MELD score                  1.098                    0.966--1.249          0.153           --      --      0.999   
  Child Pugh score            1.899                    0.972--3.710          0.061           --      --      0.995   
  Etiology of cirrhosis                                                      0.539                           1.000   
                              NBNC                     1.000                                         1.000           
                              HBV                      1.189                 0.411--2.527    0.824   --      --      0.999
                              HCV                      0.687                 0.153--3.092    0.625   --      --      0.999
                              BC                       1.849                 0.330--10.369   0.485   --      --      1.000
  Treatment                                                                  0.610                           1.000   
                              No treatment             1.000                                         1.000           
                              APC                      0.433                 0.073--2.568    0.357   --      --      1.000
                              EVL                      1.609                 0.452--5.731    0.463   --      --      0.999
                              EIS                      0.908                 0.162--5.103    0.913   --      --      0.995
  Etiology of bleeding                                                       0.293                           1.000   
                              Portal hypertension      1.000                                         1.000           
                              Peptic ulcer             2.351                 0.478--11.500           --      --      

^†^ Number of patients with 42-day mortality: 32 of all 913 patients and 6 of the 138 PPS-matched patients.

*Abbreviations*: *PPS*, propensity score; *RR*, relative risk; *CI*, confidence interval; *y/n*, yes/no; *SBP*, spontaneous bacterial peritonitis; *HCC*, hepatocellular carcinoma; *WBC*, white blood cell; *ICU*, intensive care unit; *MELD*, model for end-stage liver disease; *NBNC*, negative for both HBV and HCV; *HBV*, hepatitis B virus; *HCV*, hepatitis C virus; *BC*, presence of both HBV and HCV; *APC*, argon plasma coagulation; *EVL*, endoscopic variceal ligation; *EIS*, endoscopic injection sclerosis.

Discussion {#sec012}
==========

Antibiotic overuse is a pressing public health issue in current medical practices because antibiotics can lead to life-threatening complications \[[@pone.0229101.ref008],[@pone.0229101.ref017]\]. Thus, an effective antibiotic stewardship program requires restricting antibiotic use to subpopulations at an extremely high bacterial infection risk as well as avoiding inappropriate antibiotic use \[[@pone.0229101.ref017]\].

In clinical care for patients with cirrhosis, bacterial infection is typically a frequent and severe complication, and prophylactic antibiotic use is an integral part of patient care, particularly in patients with UGI bleeding \[[@pone.0229101.ref018]\]. Over the preceding three decades, studies investigating the role of antibiotic prophylaxis in patients with cirrhosis and UGI bleeding have demonstrated that antibiotic prophylaxis can reduce rates of bacterial infection, rebleeding, and mortality in patients with cirrhosis and UGI bleeding \[[@pone.0229101.ref006]\]. Thus, all current practice guidelines and consensus statements recommend antibiotic prophylaxis for all patients with cirrhosis and active UGI bleeding \[[@pone.0229101.ref002]--[@pone.0229101.ref004]\]. However, most studies on the role of antibiotic prophylaxis in patients with cirrhosis who have UGI bleeding have not considered the differences in bacterial infection risk levels in patients with varying degrees of liver cirrhosis \[[@pone.0229101.ref006]\].

Patients with Child--Pugh class C cirrhosis have an extremely high risk of bacterial infection, and prophylactic antibiotic use in such patients is justified, because more than half of our class C patients exhibited either documented bacterial infection or clinical signs of bacterial infection within days of UGI bleeding. However, patients with cirrhosis and low liver function impairment, namely those with Child--Pugh class A/B, are at a relatively low risk of bacterial infection, and such infections are generally less severe than those in patients with cirrhosis and high liver function impairment \[[@pone.0229101.ref019]\]. A recent study in Canada demonstrated that patients with Child--Pugh class A cirrhosis and acute variceal bleeding had low bacterial infection and mortality rates without receiving antibiotic prophylaxis \[[@pone.0229101.ref011]\]. The prophylactic effects of ceftriaxone were superior to those of cefazolin in terms of preventing infection and rebleeding only in patients categorized as Child--Pugh class B/C; this finding is indirect evidence for the low risk of bacterial infection in patients with Child--Pugh class A cirrhosis \[[@pone.0229101.ref020]\]. These observations provided the rationale for our study to reappraise the effects of antibiotic prophylaxis in patients with low Child--Pugh scores and UGI bleeding.

In addition to patients with Child--Pugh class C cirrhosis, we excluded those with documented bacterial infection on the day of UGI bleeding, with recent antibiotic use within 1 week before the UGI bleeding episode, and who died within the first 24 h, because these patients may have received or would have inevitably received antibiotic therapy for their clinical conditions. Most of these excluded patients also had Child--Pugh class C cirrhosis.

Most related studies only enrolled patients with variceal bleeding, and most of these patients exhibited alcoholism. By contrast, our study population comprised patients at ratios of 4:1 for viral versus nonviral (majorly alcoholic) cirrhosis and variceal versus peptic ulcer bleeding ([Table 1](#pone.0229101.t001){ref-type="table"}). Our results demonstrated that neither the etiology of cirrhosis nor the cause of UGI bleeding affected the patients' major outcomes. A recent study suggested that active alcohol drinkers have a high infection risk \[[@pone.0229101.ref012]\]. By contrast, patients with nonviral cirrhosis had the lower risk for infection in this study. This inconsistency warrants further investigation because our retrospective clinical information did not contain precise data regarding active drinking. Furthermore, the modality of endoscopic therapy did not affect the patient outcomes.

In our study, the proportion of patients who received antibiotic prophylaxis was only 8% (73 of 913 patients with Child--Pugh class A/B cirrhosis)---consistent with a Taiwanese study, where only 6.7% patients with cirrhosis and acute variceal bleeding received prophylactic antibiotics between 2005 and 2006 \[[@pone.0229101.ref021]\]. Even in Western studies, the percentages of patients receiving prophylactic antibiotics have been \<50% \[[@pone.0229101.ref007],[@pone.0229101.ref010],[@pone.0229101.ref011]\]. Thus, antibiotic prophylaxis may not be a common practice in both Western countries and Taiwan in the 2000s, with rates ranging from 6.67% to 49.2% \[[@pone.0229101.ref007],[@pone.0229101.ref010],[@pone.0229101.ref012],[@pone.0229101.ref021]\].

Our data revealed that 19.6% (165 of 840) of the patients who did not receive antibiotic prophylaxis exhibited clinical signs of infection and received on-demand antibiotics within 14 days of UGI bleeding. Nevertheless, the RR of complications, including bacterial infection, rebleeding, and mortality, was not higher in the patients who did not receive antibiotic prophylaxis than in those who did. Notably, the overall infection rate was 4.9% (45 of 913 patients), which is low, despite the low rate of prophylactic antibiotic use; this suggests that the role of antibiotic prophylaxis is negligible in the patients with Child--Pugh class A/B cirrhosis and UGI bleeding. In the 45 patients with documented bacterial infection, the types and sites of infection were complex and not confined to gram-negative enteric bacteria ([Table 4](#pone.0229101.t004){ref-type="table"}). The heterogeneous nature of the observed bacterial infections implicated that a broad-spectrum antibiotic should be implemented if a prophylactic regimen is intended to cover all potential pathogens.

In our study, patients with peptic ulcer bleeding received a short term intravenous PPI followed by oral PPI for 2--4 months. However, PPI use was suggested to increase the risk of SBP \[[@pone.0229101.ref022]\]. Although one multicenter prospective study indicated that PPI therapy does not increase the incidence of SBP in cirrhosis, PPIs should be administered after cautious evaluation of the indications in cirrhotic patients with UGI bleeding \[[@pone.0229101.ref023]\].

This was a retrospective study and thus has several limitations: First, we could not control for the confounding parameters; to resolve this, PPS matching was performed. Second, the prescriptions of antibiotics provided to our patients included cefazolin, cefazolin plus gentamicin, and cefuroxime and ceftriaxone; therefore, the use of antibiotic prophylaxis did not completely fit with the actual guidelines, which recommend quinolones or third-generation cephalosporins for 5--7 days after UGI bleeding. Third, no routine screening was performed for bacterial infections and therefore some occult infections may have been overlooked. Nevertheless, our findings revealed that even without routine infection workup and antibiotic use, the rate of clinically relevant infection was low. Fourth, distinguishing patients with Child--Pugh class B cirrhosis from those with class C cirrhosis can be challenging in a retrospective analysis because the factors, such as hepatic encephalopathy and ascites, are fairly subjective. Fifth, since transjugular intrahepatic portosystemic shunt has been unavailable in the study site, the impact of this therapeutic approach on the outcomes was lacking. Finally, data regarding the effects of prior bleeding episodes on patient outcomes could not be obtained because we enrolled patients with only initial UGI bleeding episodes.

Our study, nevertheless, suggests a low risk of bacterial infection in patients with low Child--Pugh scores and UGI bleeding, thus providing a rationale for additional randomized control trials comparing the differences in the effects of prophylactic versus on-demand antibiotic use in patients with low Child--Pugh scores and UGI bleeding.

Conclusions {#sec013}
===========

In patients with Child--Pugh class A/B cirrhosis and UGI bleeding, bacterial infection risk is low, and antibiotic prophylaxis has minor effects on the major outcomes. To develop an effective antibiotic stewardship program and minimize side effects, on-demand antibiotic use may be an optimal strategy for these patients. Additional randomized control trials to confirm this finding are warranted.
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